Biovectra, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. have announced a collaboration that grants Biovectra access to Revolution Biomanufacturing’s proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

This partnership provides a fully integrated pathway from mRNA sequence design through sterile drug product manufacturing, supporting customers with end-to-end development and production capabilities.

Through this alliance, sponsors gain access to a seamless workflow that begins with mRNA sequence design to improve expression and stability, followed by process development, scale-up, technology transfer, and GMP production of plasmid DNA (pDNA), mRNA, lipid nanoparticles (LNP), and sterile drug product for clinical use.

“We are thrilled to partner with Biovectra, whose deep experience in GMP manufacturing and commitment to scientific excellence make them an ideal collaborator,” said Molly McGlaughlin, CEO of Revolution Biomanufacturing. “By integrating Revolution Biomanufacturing’s advanced sequence optimization technologies with Biovectra’s end-to-end GMP manufacturing, we’re creating a clearer, more reliable path from design to drug product for our customers – one that reduces risks tied to supply disruptions, miscommunication, and failed process transfers.”

“This collaboration strengthens our ability to support innovators developing the next generation of mRNA therapeutics,” said Normand Blais, AVP, Product Development of Biovectra. “In pairing Revolution Biomanufacturing’s sequence engineering with Biovectra’s integrated development and manufacturing solutions, we’re helping developers enhance protein expression, determine sequence faster, and move to the clinic with confidence.”